Abstract
Background: Infections caused by Mycobacterium and pathogenic fungi have risen drastically over the past few decades. Moreover, with the increase in the number of immunocompromised (burn, organ transplant, chemotherapy, HIV) patients, these bacterial and fungal infections have led to alarming mortality rates. The drugs currently in use have become relatively ineffective due to ever increasing phenomenon of multidrug resistance. Furthermore, these drugs suffer with severe toxicity effects and also lack cost effectiveness.
Objective: Under such compelling circumstances, it is pertinent to find novel and safer drugs with improved properties. One strategy that could be adopted is to identify natural bioactive compounds having antimicrobial potential with minimal side effects. Alternatively, drugs synthesized with the help of combinatorial chemistry leading to enhanced antimicrobial properties could be another strategy.
Result: This article summarizes at a common platform the current scenario of the available natural as well as synthetic drugs targeting cell envelope that have patentable therapeutic interventions against predominant human bacterial and fungal pathogens.
Keywords: MDR, patent, anti-TB, antifungal, cell wall, mycolic acid, cell membrane.
Recent Patents on Biotechnology
Title:Recent Advancements in Antimycobacterial and Antifungal Drugs: A Patent Perspective
Volume: 10 Issue: 2
Author(s): Zeeshan Fatima, Rahul Pal, Moiz Ashraf Ansari and Saif Hameed
Affiliation:
Keywords: MDR, patent, anti-TB, antifungal, cell wall, mycolic acid, cell membrane.
Abstract: Background: Infections caused by Mycobacterium and pathogenic fungi have risen drastically over the past few decades. Moreover, with the increase in the number of immunocompromised (burn, organ transplant, chemotherapy, HIV) patients, these bacterial and fungal infections have led to alarming mortality rates. The drugs currently in use have become relatively ineffective due to ever increasing phenomenon of multidrug resistance. Furthermore, these drugs suffer with severe toxicity effects and also lack cost effectiveness.
Objective: Under such compelling circumstances, it is pertinent to find novel and safer drugs with improved properties. One strategy that could be adopted is to identify natural bioactive compounds having antimicrobial potential with minimal side effects. Alternatively, drugs synthesized with the help of combinatorial chemistry leading to enhanced antimicrobial properties could be another strategy.
Result: This article summarizes at a common platform the current scenario of the available natural as well as synthetic drugs targeting cell envelope that have patentable therapeutic interventions against predominant human bacterial and fungal pathogens.
Export Options
About this article
Cite this article as:
Fatima Zeeshan, Pal Rahul, Ansari Ashraf Moiz and Hameed Saif, Recent Advancements in Antimycobacterial and Antifungal Drugs: A Patent Perspective, Recent Patents on Biotechnology 2016; 10 (2) . https://dx.doi.org/10.2174/1872208310999160811170555
DOI https://dx.doi.org/10.2174/1872208310999160811170555 |
Print ISSN 1872-2083 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-4012 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Dihidro-β-Agarofuran Sesquiterpenes: A New Class of Reversal Agents of the Multidrug Resistance Phenotype Mediated by P-Glycoprotein in the Protozoan Parasite Leishmania
Current Pharmaceutical Design Graphical Abstracts
Letters in Drug Design & Discovery Proteomic Study of the Mechanism of Talin-C as an Inhibitor of HIV Infection
Current Proteomics Top Three Pharmacogenomics and Personalized Medicine Applications at the Nexus of Renal Pathophysiology and Cardiovascular Medicine
Current Pharmacogenomics and Personalized Medicine Recent Advances in the Synthesis and Development of Curcumin, its Combinations and Formulations and Curcumin-like Compounds as Anti-infective Agents
Current Medicinal Chemistry Nanotechnology: A Novel Approach for Drug Development in Health Care System
Current Nanomaterials 1-R-2-([1,2,4]Triazolo[1,5-c]quinazoline-2-ylthio)etanon(ol)s: Synthesis, Bioluminescence Inhibition, Molecular Docking Studies, Antibacterial and Antifungal Activities
Current Computer-Aided Drug Design In Vitro Antimycobacterial Activity of New 7-Chloroquinoline Derivatives
Letters in Drug Design & Discovery A Critical Review on the Unexplored Therapeutic Treasure of Himalayan Ayurvedic Drug Daruharidra (<i>Berberis Aristata</i>)
Current Traditional Medicine Virtual Screening: Are We There Yet?
Mini-Reviews in Medicinal Chemistry Traditional Chinese Medicine - Sea Urchin
Mini-Reviews in Medicinal Chemistry Adaptors in Toll-Like Receptor Signaling and their Potential as Therapeutic Targets
Current Drug Targets Surfactant Protein (SP)-A and SP-D as Antimicrobial and Immunotherapeutic Agents
Recent Patents on Anti-Infective Drug Discovery The Epidemiological and Pangenome Landscape of <i>Staphylococcus aureus</i> and Identification of Conserved Novel Candidate Vaccine Antigens
Current Proteomics Glutamate-Based Drugs for the Treatment of Clinical Depression
Central Nervous System Agents in Medicinal Chemistry Novel Small-Molecule Inhibitors of Arylamine N-Acetyltransferases: Drug Discovery by High Throughput Screening
Combinatorial Chemistry & High Throughput Screening Macrophage Targeted Cellular Carriers for Effective Delivery of Anti-Tubercular Drugs
Recent Patents on Anti-Infective Drug Discovery Brucella Carbonic Anhydrases: New Targets for Designing Anti-Infective Agents
Current Pharmaceutical Design RNA Interference-Based Therapeutics: New Strategies to Fight Infectious Disease
Infectious Disorders - Drug Targets Does Phosphodiesterase 11A (PDE11A) Hold Promise as a Future Therapeutic Target?
Current Pharmaceutical Design